<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>BodyCoding Calendar</title>
    <link>https://bodycoding.date/en/</link><description>Research updates, body education, and hands-on AI agent projects.</description><language>en</language><item><title>Can you guess which group has the higher average after splitting the data?</title><description>Switch between pooled and grouped views of a fictional dataset. The two markers have different overall averages and the same averages within each batch.</description>
        <link>https://bodycoding.date/en/cases/simpson-paradox-practice</link><guid>https://bodycoding.date/en/cases/simpson-paradox-practice</guid><pubDate>Wed, 11 Nov 2026 16:00:00 GMT</pubDate></item><item><title>How did Fractyl document its development decision?</title><description>In its October 22, 2026 disclosure, Fractyl said it would stop internal development of its Rejuva gene therapy program and explore other options.</description>
        <link>https://bodycoding.date/en/cases/fractyl-rejuva-disclosure</link><guid>https://bodycoding.date/en/cases/fractyl-rejuva-disclosure</guid><pubDate>Tue, 10 Nov 2026 16:00:00 GMT</pubDate></item><item><title>Read a GLP‑1 drug labeling update</title><description>On November 9, 2026, the U.S. FDA announced required GLP‑1 receptor agonist labeling changes concerning the potential risk of NAION, a rare optic nerve disorder.</description>
        <link>https://bodycoding.date/en/cases/fda-glp-1-naion-label</link><guid>https://bodycoding.date/en/cases/fda-glp-1-naion-label</guid><pubDate>Mon, 09 Nov 2026 16:00:00 GMT</pubDate></item><item><title>What did the early CTX310 study measure?</title><description>On November 9, 2026, CRISPR Therapeutics announced Phase 1b results for CTX310, reporting changes in blood lipid measures among participants with severe hypertriglyceridemia.</description>
        <link>https://bodycoding.date/en/cases/ctx310-early-clinical-evidence</link><guid>https://bodycoding.date/en/cases/ctx310-early-clinical-evidence</guid><pubDate>Sun, 08 Nov 2026 16:00:00 GMT</pubDate></item><item><title>Build a one-page follow-up summary from eight sample records</title><description>This demo sorts fictional follow-up records by date and puts weights, notes, and questions for a clinician on one printable page.</description>
        <link>https://bodycoding.date/en/cases/follow-up-record-demo</link><guid>https://bodycoding.date/en/cases/follow-up-record-demo</guid><pubDate>Sat, 07 Nov 2026 16:00:00 GMT</pubDate></item><item><title>Read STEP 1 as a randomized controlled trial</title><description>This 2021 double-blind study compared weight outcomes with semaglutide and placebo in adults with overweight or obesity without diabetes over 68 weeks.</description>
        <link>https://bodycoding.date/en/cases/step-1-study-reading</link><guid>https://bodycoding.date/en/cases/step-1-study-reading</guid><pubDate>Thu, 05 Nov 2026 16:00:00 GMT</pubDate></item><item><title>What does genome editing change?</title><description>The National Human Genome Research Institute explains genome editing and why researchers study the relationship between DNA changes and traits.</description>
        <link>https://bodycoding.date/en/cases/what-genome-editing-changes</link><guid>https://bodycoding.date/en/cases/what-genome-editing-changes</guid><pubDate>Tue, 03 Nov 2026 16:00:00 GMT</pubDate></item><item><title>How are GLP‑1 and GLP‑1 receptor agonists related?</title><description>The World Health Organization explains the role of the body&#39;s GLP‑1 signal and how related medicines mimic it.</description>
        <link>https://bodycoding.date/en/cases/who-glp-1-explainer</link><guid>https://bodycoding.date/en/cases/who-glp-1-explainer</guid><pubDate>Sun, 01 Nov 2026 16:00:00 GMT</pubDate></item></channel></rss>